NEW YORK (GenomeWeb News) – Spanish healthcare and biopharmaceutical manufacturing firm Grifols today announced a deal with Novartis Diagnostics to commercialize certain Grifols products in the US.
Following regulatory approval in the US, the Novartis business would market and distribute Grifols' immunohematology instruments, assays, and other products, under the terms of the deal. Novartis will also market and distribute semi-automated, pre-transfusion diagnostic products made by subsidiaries of Grifols and Progenika blood group antigen genotyping products that are currently distributed by Grifols.
During the summer, Grifols and Progenika partnered on a distribution deal covering Progenika's microchip blood typing technology called Bloodchip.
Financial and other terms of today's agreement were not disclosed.
In a statement, Grifols, based in Barcelona, Spain, said that Novartis will help strengthen its position in the US. It added that currently more than 80 percent of the US blood supply is tested on Novartis' testing platforms, which were co-developed with molecular diagnostics firm Gen-Probe.
According to a Novartis spokesperson, the deal launches the firm into the blood genotyping market.
Novartis said in a statement that "[a]lthough the use of molecular biology tests in transfusion compatibility testing is still at its early stages, its use is expected to become more widespread as a result of hemovigilance and transfusion safety plans being introduced in many countries."